Telotristat etiprate for carcinoid syndrome: A single-arm, multicenter trial

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 4, 2015, Pages 1511-1519

  Pavel, Marianne ^a   Hörsch, Dieter ^b   Caplin, Martyn ^c   Ramage, John ^d   Seufferlein, Thomas ^e   Valle, Juan ^f   Banks, Phillip ^g   Lapuerta, Pablo ^g   Sands, Arthur ^g   Zambrowicz, Brian ^g   Fleming, Douglas ^g   Wiedenmann, Bertram ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ZENTRALKLINIK BAD BERKA   (Germany)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^d BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; CHROMOGRANIN A; GAMMA GLUTAMYLTRANSFERASE; LOPERAMIDE; OCTREOTIDE; SEROTONIN; TELOTRISTAT ETIPRATE; PHENYLALANINE; PYRIMIDINE DERIVATIVE; TELOTRISTAT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CARCINOID; CARCINOID SYNDROME; CLINICAL ARTICLE; DEFECATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FECES ANALYSIS; FEMALE; FLATULENCE; FLUSHING; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GERMANY; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; LETHARGY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; ORTHOSTATIC INTOLERANCE; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; TREATMENT OUTCOME; UNITED KINGDOM; UPPER ABDOMINAL PAIN; URINALYSIS; VERY ELDERLY; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; GASTROINTESTINAL TRANSIT; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; URINE;

ABDOMINAL PAIN; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUSHING; GASTROINTESTINAL TRANSIT; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; PHENYLALANINE; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84927610999     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2247     Document Type: Article

References (13)

1. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89:151-160.
2. Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41:461-466.
3. Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg. 1996;20:126-131.
4. Møller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348:1005-1015.
5. Dobson R, Burgess MI, Banks M, et al. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One. 2013;8:e73679.
6. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31:169-188.
7. Öberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-enter-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii124-vii130.
8. Öberg K. Interferon in the management of neuroendocrine GEPtumors: a review. Digestion. 2000;62(suppl 1):92-97.
9. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:196.
10. Ray D, Williams G. Pathophysiological causes and clinical significance of flushing. Br J Hosp Med. 1993;50:594-598.
11. Balks HJ, Conlon JM, Creutzfeldt W, Stöckmann F. Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush. Eur J Clin Pharmacol. 1989;36:133-137.
12. Engelman K, Lovenberg W, Sjoerdsma A. Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome. N Engl J Med. 1967;277:1103-1108.
13. Kulke MH, O'Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705-714.